KDA
- Current
- Browse
- Collections
-
For contributors
- For Authors
- Instructions to authors
- Article processing charge
- e-submission
- For Reviewers
- Instructions for reviewers
- How to become a reviewer
- Best reviewers
- For Readers
- Readership
- Subscription
- Permission guidelines
- About
- Editorial policy
Search
- Page Path
- HOME > Search
- Genetics
- Severity of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus: Relationship between Nongenetic Factors and PNPLA3/HSD17B13 Polymorphisms
- Mattia Bellan, Cosimo Colletta, Matteo Nazzareno Barbaglia, Livia Salmi, Roberto Clerici, Venkata Ramana Mallela, Luigi Mario Castello, Giuseppe Saglietti, Gian Piero Carnevale Schianca, Rosalba Minisini, Mario Pirisi
- Diabetes Metab J. 2019;43(5):700-710. Published online July 29, 2019
- DOI: https://doi.org/10.4093/dmj.2018.0201
- 4,933 View
- 76 Download
- 16 Web of Science
- 17 Crossref
-
Abstract
PDF
PubReader Background The prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM) is high, though its severity is often underestimated. Our aim is to provide an estimate of the prevalence of severe NAFLD in T2DM and identify its major predictors.
Methods T2DM patients (
n =328) not previously known to have NAFLD underwent clinical assessment, transient elastography with measure of liver stiffness (LS) and controlled attenuation parameter (CAP), and genotyping for patatin like phospholipase domain containing 3 (PNPLA3 ) and 17β-hydroxysteroid-dehydrogenase type 13 (HSD17B13 ).Results Median LS was 6.1 kPa (4.9 to 8.6). More than one-fourth patients had advanced liver disease, defined as LS ≥7.9 kPa (
n =94/238, 29%), and had a higher body mass index (BMI) than those with a LS <7.9 kPa. Carriage of the G allele in thePNPLA3 gene was associated with higher LS, being 5.9 kPa (4.7 to 7.7) in C/C homozygotes, 6.1 kPa (5.2 to 8.7) in C/G heterozygotes, and 6.8 kPa (5.8 to 9.2) in G/G homozygotes (P =0.01). This trend was absent in patients with ≥1 mutatedHSD17B13 allele. In a multiple linear regression model, BMI andPNPLA3 genotype predicted LS, while age, gender, disease duration, and glycosylated hemoglobin did not fit into the model. None of these variables was confirmed to be predictive among carriers of at least oneHSD17B13 mutated allele. There was no association between CAP and polymorphisms ofPNPLA3 orHSD17B13 .Conclusion Advanced NAFLD is common among T2DM patients. LS is predicted by both BMI and
PNPLA3 polymorphism, the effect of the latter being modulated by mutatedHSD17B13 .-
Citations
Citations to this article as recorded by
- miRNA and lncRNA as potential tissue biomarkers in hepatocellular carcinoma
Venkata Ramana Mallela, Marie Rajtmajerová, Andriy Trailin, Václav Liška, Kari Hemminki, Filip Ambrozkiewicz
Non-coding RNA Research.2024; 9(1): 24. CrossRef - 17-Beta-Hydroxysteroid Dehydrogenase 13 Loss of Function Does Not Confer Protection to Nonalcoholic Fatty Liver Disease in Indian Population
Bale Govardhan, V. Kulkarni Anand, Padaki Nagaraja Rao, P. Balachandran Menon, Sharma Mithun, Mitnala Sasikala, T.R. Sowmya, Sekaran Anuradha, C. Pawar Smita, D. Nageshwar Reddy, Vishnubhotla Ravikanth
Journal of Clinical and Experimental Hepatology.2024; 14(4): 101371. CrossRef - Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD
Maral Amangurbanova, Daniel Q. Huang, Rohit Loomba
Alimentary Pharmacology & Therapeutics.2023; 57(1): 37. CrossRef - Identification of shared genetic architecture between non-alcoholic fatty liver disease and type 2 diabetes: A genome-wide analysis
Yajing Tan, Qian He, Kei Hang Katie Chan
Frontiers in Endocrinology.2023;[Epub] CrossRef - Polymorphisms of HSD17B13, GCKR, HFE, and CP as factors of the development of non-alcoholic fatty liver disease and comorbid diseases
O. V. Smirnova, D. V. Lagutinskaya
Meditsinskiy sovet = Medical Council.2023; (8): 119. CrossRef - Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis
Elina En Li Cho, Chong Zhe Ang, Jingxuan Quek, Clarissa Elysia Fu, Lincoln Kai En Lim, Zane En Qi Heng, Darren Jun Hao Tan, Wen Hui Lim, Jie Ning Yong, Rebecca Zeng, Douglas Chee, Benjamin Nah, Cosmas Rinaldi Adithya Lesmana, Aung Hlaing Bwa, Khin Maung W
Gut.2023; 72(11): 2138. CrossRef - HSD17B13 and other liver fat-modulating genes predict development of hepatocellular carcinoma among HCV-positive cirrhotics with and without viral clearance after DAA treatment
Michela E. Burlone, Mattia Bellan, Matteo N. Barbaglia, Ginevra Mocchetti, Venkata R. Mallela, Rosalba Minisini, Cristina Rigamonti, Mario Pirisi
Clinical Journal of Gastroenterology.2022; 15(2): 301. CrossRef - Influence of Type 2 Diabetes in the Association of PNPLA3 rs738409 and TM6SF2 rs58542926 Polymorphisms in NASH Advanced Liver Fibrosis
Pablo Gabriel-Medina, Roser Ferrer-Costa, Francisco Rodriguez-Frias, Andreea Ciudin, Salvador Augustin, Jesus Rivera-Esteban, Juan M. Pericàs, David Martinez Selva
Biomedicines.2022; 10(5): 1015. CrossRef - Triglyceride and glucose index is a simple and easy‐to‐calculate marker associated with nonalcoholic fatty liver disease
Kyung‐Soo Kim, Sangmo Hong, Hong‐Yup Ahn, Cheol‐Young Park
Obesity.2022; 30(6): 1279. CrossRef - Prevalence of elevated liver stiffness in patients with type 1 and type 2 diabetes: A systematic review and meta-analysis
Stefano Ciardullo, Gianluca Perseghin
Diabetes Research and Clinical Practice.2022; 190: 109981. CrossRef - Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease
Wen-Yue Liu, Mohammed Eslam, Kenneth I. Zheng, Hong-Lei Ma, Rafael S. Rios, Min-Zhi Lv, Gang Li, Liang-Jie Tang, Pei-Wu Zhu, Xiao-Dong Wang, Christopher D. Byrne, Giovanni Targher, Jacob George, Ming-Hua Zheng
Journal of Clinical and Translational Hepatology.2021; 000(000): 000. CrossRef - Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Eugene Han, Mi Kyung Kim, Byoung Kuk Jang, Hye Soon Kim
Diabetes & Metabolism Journal.2021; 45(5): 698. CrossRef - Genetic Polymorphisms and Clinical Features in Diabetic Patients With Fatty Liver: Results From a Single-Center Experience in Southern Italy
Rosanna Villani, Grazia Pia Magnati, Giuseppe De Girolamo, Moris Sangineto, Antonino Davide Romano, Tommaso Cassano, Gaetano Serviddio
Frontiers in Medicine.2021;[Epub] CrossRef - Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients
Carla De Benedittis, Mattia Bellan, Martina Crevola, Elena Boin, Matteo Nazzareno Barbaglia, Venkata Ramana Mallela, Paolo Ravanini, Elisa Ceriani, Stefano Fangazio, Pier Paolo Sainaghi, Michela Emma Burlone, Rosalba Minisini, Mario Pirisi
Gastroenterology Research and Practice.2020; 2020: 1. CrossRef - Toward Genetic Prediction of Nonalcoholic Fatty Liver Disease Trajectories: PNPLA3 and Beyond
Marcin Krawczyk, Roman Liebe, Frank Lammert
Gastroenterology.2020; 158(7): 1865. CrossRef - The effect of liraglutide on nonalcoholic fatty liver disease in type 2 diabetes mellitus
Xueyang Zhang, Ran Bai, Yong Jia, Junwei Zong, Yongbo Wang, Yanan Dong
International Journal of Diabetes in Developing Countries.2020; 40(4): 491. CrossRef - Lifestyle and silymarin: a fight against liver damage in NAFLD associated - prediabetic disease
Cosimo Colletta, Alessandro Colletta, Giuseppe Placentino
Journal of Diabetes & Metabolic Disorders.2020; 19(2): 883. CrossRef
- miRNA and lncRNA as potential tissue biomarkers in hepatocellular carcinoma
First
Prev
